Keyword: Reckitt Benckiser Pharmaceuticals
RB's Mucinex brand saw high spikes in brand awareness and purchase intent fueled by a high-visibility pre- and post-Super Bowl campaign.
Reckitt Benckiser is officially bowing out of the race for Pfizer’s consumer health unit, paving the way for GlaxoSmithKline to make a move.
Reports say that Nestle backed off as leader to buy Merck KGaA’s consumer businesses and that Pfizer has only two interested parties.
Pharma companies didn't air any Super Bowl advertisements for the second year in a row, although Reckitt's OTC brand Mucinex did buy into the postgame slot.
Johnson & Johnson has plenty of money coming in from overseas, thanks to U.S. tax reform. But it won’t be spending it on Pfizer’s OTC unit.
GSK and Reckitt Benckiser have already declared interest in Pfizer’s consumer health unit. But they likely won’t be alone when bidding kicks off.
Reckitt Benckiser, rumored to be eyeing a bid for Pfizer’s OTC unit, is making some big changes to its own consumer health operations.
Reckitt Benckiser’s feelings about Pfizer’s OTC unit haven’t changed since the company said it’d be keen to buy it. But its resources have.
Thirty-five U.S. states and the District of Columbia have filed suit against the U.K.'s Indivior, alleging anticompetitive actions for the opioid Suboxone and seeking to “disgorge” the company's "ill-gotten” gains.
Reckitt Benckiser has been hit with two major scandals over the weekend as the British consumer healthcare and drug company is forced to apologize for misleading customers and selling products that killed or injured people.